CTLA4 and neoplasm: We found that addition of a depleting antibody for CD25+ T cells, GR1 expressing myeloid cells, and Ly6G+ cells significantly inhibited the resistance to anti-PD-1/CTLA-4, but did not produce complete tumor regressions.